Abiraterone in Metastatic Prostate Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
   Trial
2. Probing the Relationship Between the Human Gut Microbiome and Prospects of Prostate Cancer: A Systematic Review.Cureus · 2023
   Review
3. The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer.The Journal of urology · 2023
   Article
4. A cost-utility analysis of apalutamide for metastatic castrationsensitive prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022
   Article
5. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.European urology open science · 2021
   Article
6. Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion.ESMO open · 2020
   Review
7. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.JCO precision oncology · 2020
   Article
8. Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).Advances in therapy · 2018
   Article
9. Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP.Oncotarget · 2018
   Article

Corrections and comments

• Comment on
  Abiraterone in Metastatic Prostate Cancer.2017
• Comment on
  Abiraterone in Metastatic Prostate Cancer.2017

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as